000 01393 a2200385 4500
005 20250516231455.0
264 0 _c20151008
008 201510s 0 0 eng d
022 _a1573-2665
024 7 _a10.1007/s10545-014-9758-8
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aSchiffmann, Raphael
245 0 0 _aThe consequences of genetic and pharmacologic reduction in sphingolipid synthesis.
_h[electronic resource]
260 _bJournal of inherited metabolic disease
_cJan 2015
300 _a77-84 p.
_bdigital
500 _aPublication Type: Journal Article; Review
650 0 4 _aAnimals
650 0 4 _aAsthma
_xgenetics
650 0 4 _aAtherosclerosis
_xgenetics
650 0 4 _aDiabetes Mellitus
_xgenetics
650 0 4 _aDisease Models, Animal
650 0 4 _aGlucose
_xchemistry
650 0 4 _aGlucosyltransferases
_xgenetics
650 0 4 _aHumans
650 0 4 _aLipid Metabolism
_xgenetics
650 0 4 _aLysosomes
_xmetabolism
650 0 4 _aMice
650 0 4 _aPolycystic Kidney Diseases
_xgenetics
650 0 4 _aSerine C-Palmitoyltransferase
_xgenetics
650 0 4 _aSphingolipidoses
_xgenetics
650 0 4 _aSphingolipids
_xbiosynthesis
650 0 4 _aUridine Diphosphate
_xchemistry
773 0 _tJournal of inherited metabolic disease
_gvol. 38
_gno. 1
_gp. 77-84
856 4 0 _uhttps://doi.org/10.1007/s10545-014-9758-8
_zAvailable from publisher's website
999 _c24137458
_d24137458